Volume : 09, Issue : 06, June – 2022

Title:

52.NANOSUSPENSION: AN AUSPECIOUS PRESENT – DAY STRATEGY TO IMPROVE SOLUBILITY AND TO ENHANCE BIOAVAILABILITY OF POORLY SOLUBLE DRUG ALONG WITH SAFETY AND EFFICACY: A REVIEW
‬

Authors :

Vishakha Devi*, Gopal Thakur*

Abstract :

The present article describes that how the nanosuspension technique is the most useful technique to deliver the drug having poor solubility. As we all know, that according to the BCS classification two and four most of the drug have poor solubility. Due to the poor solubility, these drugs are not absorbed well and have low bioavailability. To resolve this complication, many techniques are used such as micronization, use of penetration enhancers, use of solvent and co solvents etc. but those plans of action are most effectively beneficial for magnify the solubility of hydrophobic drugs. So, nanosuspension is the most effective method left which supply the medicine with better solubility and bioavailability. Utmost typically to prepare best nanosuspension formulations either media milling technique is used or if it is not employed then in place of this high-pressure homogenization technique gives the best result. In nanosuspension the drug are put up in dispersion and stabilizes via way of means of surfactants. This article, signifies how the nanosuspensions will prepared or what are the techniques employed to prepare best nanosuspensions formulation, secondaly it explains that if we prepared nanosuspensions then how we know that the nanosuspensions are actually prepared i.e characterization and at last this article explain how these nanosuspensions are deliver into our body i.e applications. Nanosuspension intensify now no longer simply the solubility however additionally the safety and efficacy of the drug. The nanosuspensions are deliver via oral route, transdermal route, parenteral route, pulmonary route, ocular route etc.
Keywords: Nanosuspension technique, Solubility, Homogenization, BCS, Bioavailability.

Cite This Article:

Please cite this article in press Vishakha Devi et al, Nanosuspension: An Auspicious Present – Day Strategy To Improve Solubility And To Enhance Bioavailability Of Poorly Soluble Drug Along With Safety And Efficacy: A Review., Indo Am. J. P. Sci, 2022; 09(6).,

Number of Downloads : 10

References:

1. Lakshmi P, Ashwini KG. Nanosuspension technology: A review. Int J Pharm Sci 2010;2:35-40.
2. Geetha G, Poojitha U, Arshad Ahmed K. International Journal of Pharma Research and review, 2014; 3(9): 30-37.
3. Nagaraju P, Krishnachaithanya K, Srinivas VD, Padma SV. Nanosuspensions: A promising drug delivery systems.Int J Pharm Sci Nano 2010;2:679-84.
4. Date AA, Kulkarni RM and Patravale VB: Nanosuspensions: A promising drug delivery.Journal of Pharmacy & Pharmacology 2018; 56 : 827-40.
5. Vaneerdenbrugh B, Vandenmooter G, Augustijns P. International Journal of Pharmaceutics, 2008; 364(1):64–75.
6. Dewaard H, Hinrichs W, Frijlink H. Journal of Control Release, 2008; 128 (2): 179-83.
7. Nash R.A. Suspensions. In: Swarbrick J, Boylan J.C (Ed). Encyclopedia of pharmaceutical technology. Second edition vol. 3. New York, Marcel Dekker, 2002; p. 2045 – 3032.
8. Keck C, Muller R. European Journal of Pharmaceutics and Biopharmaceutics, 2006; 62(1):3–16.
9. Muller RH, Jacobs C and Kayer O. Nanosuspensions for the formulation of poorly soluble drugs. In: F Nielloud, G Marti-Mestres (Ed). Pharmaceutical emulsion and suspension. New York, Marcel Dekker, 2000, p. 383 -407.
10. Kumari K, Rao S. Nanosuspension: A Review, International journal of pharmacy 2017;7(2):77-89.
11. Cornelia M Keck, Rainer H. Muller. European Journal of Pharmaceutics and Biopharmaceutics, 2006; 62:3 –16.
12. Kipp JE, Wong J, Doty M, Werling J, Rebbeck C, Brynjelsen S. Method for preparing submicron particle suspensions. US Patent, 0031719 A1, 2003.
13. Noyes AA, Whitney WR. The rate of solution of solid substances in their own solutions. J Am Chem Soc 1897;19:930-4.
14. Hintz RJ, Johnson KC. The effect of particle size distribution on dissolution rate and oral absorption. Int J Pharm 1989;51:9-17.
15. Deans R. Atovaquone pharmaceutical compositions. US Patent US 6018080, 2000.
16. Liversidge GG, Cundy KC, Bishop JF and Czekai DA. Surface modified drug nanoparticles. US Patent 5; 1999
17. Patravale, AA Date and RM Kulkarni VB. Journal of Pharmacology and pharmacotherapeutics, 2004; 56:827-40.
18. Wongmekiat A, Tozuka Y, Oguchi T, Yamamoto K. Formation of fine drug particles by cogrinding with cyclodextrins. I The use of β –cyclodextrin anhydrate and hydrate. Pharm Res. 2002;19(12):1867 – 72.
19. Itoh K, Pongpeerapat A, Tozuka Y, Oguchi T, Yamamoto K. Nanoparticle formation of poorly water soluble drugs from ternary ground mixtures with PVP and SDS. Chem Pharm Bull 2003;51:171-4.
20. Mura P, Cirri M, Faucci MT, Gines-Dorado JM, Bettinetti GP. Investigation of the effects of grinding and co-grinding on physicochemical properties of glisentide. J Pharm Biomed Anal 2002;30:227-37.
21. Yarraguntla Rao S. ,Kumari Kamala p. ,Nanosuspension : a Review International journal of pharmacy, 2017;7(2): 77-89.
22. Young TJ, Mawson S, Johnston KP, Henriska IB, Pace GW, Mishra AK. Biotechnology Progress, 2000; 16:402–7.
23. Liversidge GG, Cundy KC. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int J Pharm 1995;125:91-7.
24. Chen Y, Liu, J, Yang X, Zhao X, Xu H. Oleanolic acid nanosuspensions: Preparation, in-vitro characterization and enhanced hepatoprotective effect. J Pharm Pharmacol 2005;57:259-64.
25. Higgins JP. Spectroscopic approach for on-line monitoring of particle size during the processing of pharmaceutical nanoparticles. Anal Chem 2003;75:1777-85.
26. Kumar AN, Deecaraman M, Rani C. Nanosuspension technology and its applications in drug delivery. Asian J Pharma 2009;3:168-73
27. Young TJ, Mawson S, Johnston KP, Henriska IB, Pace GW, Mishra AK. Rapid expansion from supercritical to aqueous solution to produce submicron suspension of water insoluble drugs. Biotechnol Prog 2000;16:402-7.
28. Setler P. Identifying new oral technologies to meet your drug delivery needs for the delivery of peptides and proteins and poorly soluble molecules. London: IIR Limited Drug delivery system; 1999.
29. Muller RH, Jacobs C. Production and characterization of a budesonide nanosuspension for pulmonary administration. Pharm Res 2002;19:189-94
30. Yang JZ, Young AL, Chiang PC, Thurston A, Pretzer DK. Fluticasone and budesonide nanosuspensions for pulmonary delivery: Preparation, characterization, and pharmacokinetic studies. J Pharm Sci 2008;97:4869-78.
31. Liang YC, Binner JG. Effect of triblock copolymer non-ionic surfactants on the rheology of 3 mol% yttria stabilised zirconia nanosuspensions. Ceram Int 2008;34:293-7.
32. Muller RH, Grau MJ. Increase of dissolution rate and solubility of poorly water soluble drugs as nanosuspension. Proceedings. World Meeting APGI/APV, Paris. 1998;2:62-624
33. Sonkambale G.K., Katedeshmukh G.R., Kumbhar B. A. European Journal of Molecular and Clinical Medicine Volume- 08, 2021
34. Patel R. V. and Agrawal K.Y.: Nanoparticulate dispersion systems, Journal Of Advanced pharmaceutical technology and research Vol. 2, 2011.
35. Gabor F, Fillafer C, Neutsch L, Ratzinger G and Wirth M, Drug Delivery, 2010; 197:345 – 398.
36. Jia L, Wong H, Cerna C, Weitman SD. Effect of nanonization on absorption of 301029: Ex vivo and in vivo pharmacokinetic correlations determined by liquid chromatography/mass spectrometry. Pharm Res 2002;19:1091-6.
37. Liversidge EM. Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs. Pharm Res 1996;13:272-8.
38. Liversidge EM, Liversidge GG, Cooper ER. Nanosizing: A formulation approach for poorly-water- soluble compounds. Eur J Pharm Sci 2003;18:113-20.
39. Sastry SV, Nyshadham JR, and Fix JA, Pharmaceutical Science and Technology Today, 2000; 3(4):138 – 145.
40. Hernandez-Trejo N, Kayser O, Steckel H, Muller RH. Characterization of nebulized bupravaquone nanosuspensionsEffect of nebulization technology. J Drug Target 2005;13:499-507.
41. Heidi MM, Yun-Seok R, Xiao W. Nanomedicine in pulmonary delivery. Int J Nanomed 2009;4:299-319.
42. Beck-Broichsitter M, Pulmonary drug delivery with nanoparticles, in Nanomedicine in Health and Disease, Hunter RJ and Preedy VR , Eds., 2011, 229–248, CRC Press, New York, NY, USA.
43. Dhiman S, Singh TG and Dharmila, International Journal of Current Pharmaceutical Research, 2011; 3(4):96–101.
44. Bailey MM and Berkland CJ, Medicinal Research Reviews, 29 (1); 2009:196–212.
45. Foster KA, Yazdanian M and Audus KL, Journal of Pharmacy and Pharmacology, 2001; 53(1):57–66.
46. 3. Liversidge EM, Liversidge GG, Cooper ER. Nanosizing: A formulation approach for poorly-water- soluble compounds. Eur J Pharm Sci 2003;18:113-20.
47. Peters K, Leitzke S, Diederichs JE, Borner K, Hahn H, Muller RH, et al. Preparation of a clofazamine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection. J Antimicrob Chemother 2000;45:77-83.
48. Rainbow B, Kipp J, Papadopoulos P, Wong J, Glosson J, Gass J, et al. Itraconazole IV nanosuspension enhances efficacy through altered pharmacokinetic in the rat. Int J Pharm 2007;339:251-60.
49. Boedeker BH, Lojeski EW, Kline MD, Haynes DH. Ultra-long duration local anesthesia produced by injection of lecithin-coated tetracaine microcrystals. J Clin Pharmacol 1994;34:699-702
50. Gaudana R, Jwala J, Boddu SHS , and Mitra AK , Pharmaceutical Research, 2009; 26 (5):1197–1216.
51. Bhalla S, Parenteral drug delivery, in Gibaldi’s Drug Delivery Systems in Pharmaceutical Care, M. Lee and A. Desai, Eds., p. 107, ASHP, Bethesda, Md,SA, 2007.
52. Kayser O. Nanosuspensions for the formulation of aphidicolin to improve drug targeting effects against Leishmania infected macrophages. Int J Pharm 2000;196:253-6.
53. Scholer N, Krause K, Kayser O, Moller RH, Borner K, Hahn H, et al.Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplamosis. Antimicrob Agents Chemother 2001;45:1771-9.
54. Subramanian S., Devi K. M., Rajesh V.C., Preparation, evaluation and optimization of atorvastatin nanosuspension incorporated transdermal patch, Asian Journal of Pharmaceutics 2016, 10(4).